Peripheral T-cell Lymphoma: Clinical Trials

59 trials for Peripheral T-cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

33 completed, 12 terminated, 7 recruiting, 3 unknown. 59 Phase 1, 21 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 159Completed 33, Terminated 12, Recruiting 7, Unknown 3, Not yet recruiting 2, Active not recruiting 1, Suspended 1
Phase 221Completed 9, Recruiting 4, Terminated 4, Unknown 2, Active not recruiting 1, Not yet recruiting 1

Follow Peripheral T-cell Lymphoma: new trials by email Literature Review of Peripheral T-cell Lymphoma trials Research Report on Peripheral T-cell Lymphoma

Trials (filtered) newest first · largest first

All 59 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Phase 1 / Phase 2RecruitingBeijing Biotech962026-03-022026-04-13
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
C7R.CD30.CAR-EBVST cells - CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type
Phase 1RecruitingBaylor College of Medicine902025-10-272026-10-02
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma
Phase 1SuspendedNational Cancer Institute (NCI)602025-09-292026-10-16
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended) - Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma
Phase 1 / Phase 2RecruitingEvopoint Biosciences Inc.1762025-08-152026-07-29
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
BITR2101 - NHL, Cutaneous T Cell Lymphoma
Phase 1Not yet recruitingBoston Immune Technologies and Therapeutics372025-08-012025-07-08
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
CHT101 - Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL)
Phase 1RecruitingTianjin Medical University Cancer Institute and Hospital242025-03-312025-04-06
Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma
chidamide and golidocitinib - Peripheral T-cell Lymphoma
Phase 1 / Phase 2Not yet recruitingPeking University Cancer Hospital & Institute452024-12-302025-01-03
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
Golidocitinib plus CHOP - Peripheral T-cell Lymphoma
Phase 1 / Phase 2RecruitingPeking Union Medical College Hospital682024-09-012024-12-18
Linperlisib Combined With Chidamide in Patients With PTCL
Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone - Peripheral T-cell Lymphoma
Phase 1 / Phase 2RecruitingYanyan Liu1342024-05-252025-12-05
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
SHR2554/CHOP, SHR2554/CHOEP - Peripheral T-cell Lymphoma
Phase 1 / Phase 2UnknownJiangsu HengRui Medicine Co., Ltd.1002023-12-222024-05-14
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma
Phase 1RecruitingSciTech Development, Inc.462023-12-182026-10-05
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
Linperlisib in combination with CHOP - Peripheral T-cell Lymphoma
Phase 1 / Phase 2Active not recruitingSun Yat-sen University442023-08-152026-09-16
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma
Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP) - Peripheral T-cell Lymphoma
Phase 1UnknownTianjin Medical University Cancer Institute and Hospital182022-07-072022-07-14
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin - Treatment, Peripheral T-cell Lymphoma
Phase 1 / Phase 2UnknownPeking Union Medical College Hospital602022-05-012022-07-01
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Parsaclisib, Chidamide - Peripheral T-Cell Lymphoma
Phase 1TerminatedHenan Cancer Hospital122022-02-202025-12-02
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies
Phase 1CompletedNational Cancer Institute (NCI)262020-12-172026-10-14
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab - Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
Phase 1 / Phase 2TerminatedAntengene Corporation562020-08-182026-01-05
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
SEA-TGT, sasanlimab, brentuximab vedotin - Non-small Cell Lung Cancer, Gastric Carcinoma
Phase 1TerminatedSeagen Inc.1332020-05-292025-02-10
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma
AK104 - Peripheral T-cell Lymphoma
Phase 1 / Phase 2TerminatedAkeso62020-05-152022-10-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Romidepsin, Busulfan, Fludarabine - Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia
Phase 1CompletedOhio State University Comprehensive Cancer Center232017-12-082025-09-19

Showing 20 of 59. Sign in to see all of them.

Narrower conditions

Lymphoma, T-Cell, Peripheral (59)  ·  Lymphoma, T-Cell, Cutaneous (23)  ·  Lymphoma, Extranodal NK-T-Cell (22)  ·  Lymphoma, Large B-Cell, Diffuse (22)  ·  Lymphoma, Large-Cell, Anaplastic (22)  ·  Immunoblastic Lymphadenopathy (21)  ·  Lymphoma, Non-Hodgkin (21)  ·  Mycosis Fungoides (21)  ·  Sezary Syndrome (20)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (19)  ·  Lymphoma, Follicular (19)  ·  Lymphoma, Mantle-Cell (19)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (19)  ·  Burkitt Lymphoma (18)  ·  Lymphoma, B-Cell, Marginal Zone (18)

Broader conditions

Hemic and Lymphatic Diseases (59)  ·  Immune System Diseases (59)  ·  Immunoproliferative Disorders (59)  ·  Lymphatic Diseases (58)  ·  Lymphoproliferative Disorders (58)  ·  Neoplasms by Histologic Type (58)  ·  Neoplasms (57)  ·  Lymphoma, T-Cell (55)  ·  Lymphoma (52)  ·  Lymphoma, Non-Hodgkin (38)  ·  Hematologic Diseases (31)  ·  Leukemia, Lymphoid (29)  ·  Leukemia (28)  ·  Disease Attributes (23)  ·  Pathologic Processes (23)

Interventions

Cyclophosphamide (6)  ·  Doxorubicin (5)  ·  Prednisone (5)  ·  Vincristine (5)  ·  Etoposide (4)  ·  Lenalidomide (4)  ·  N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (4)  ·  fludarabine phosphate (4)  ·  Dexamethasone (3)  ·  Gemcitabine (3)  ·  Peripheral Blood Stem Cell Transplantation (3)  ·  romidepsin (3)  ·  10-propargyl-10-deazaaminopterin (2)  ·  Azacitidine (2)  ·  Bendamustine Hydrochloride (2)

Sponsors

National Cancer Institute (NCI) (7)  ·  Fred Hutchinson Cancer Center (3)  ·  Acrotech Biopharma Inc. (2)  ·  City of Hope Medical Center (2)  ·  Massachusetts General Hospital (2)  ·  Peking Union Medical College Hospital (2)  ·  Solasia Pharma K.K. (2)  ·  Tianjin Medical University Cancer Institute and Hospital (2)  ·  AbbVie (prior sponsor, Abbott) (1)  ·  Aileron Therapeutics, Inc. (1)  ·  Akeso (1)  ·  Amir Mortazavi (1)  ·  Antengene Corporation (1)  ·  Aptevo Therapeutics (1)  ·  Asana BioSciences (1)

Countries

United States (37)  ·  China (13)  ·  Canada (5)  ·  Japan (4)  ·  Italy (3)  ·  Argentina (1)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Jeremy Abramson, MD (2)  ·  Aaron R Mangold, M.D. (1)  ·  Adam Petrich, MD (1)  ·  Ajay Gopal (1)  ·  Ali Moiin, MD (1)  ·  Amir Mortazavi, MD (1)  ·  Andres Forero-Torres, MD (1)  ·  Ann F Mohrbacher, MD (1)  ·  Anthony J Reiman (1)  ·  Auris O Huen, MD, PharmD (1)  ·  Barbara Pro, MD (1)  ·  Brad Haverkos, M.D. (1)  ·  Brenda Sandmaier (1)  ·  Christiane Querfeld, M.D., Ph.D. (1)  ·  Craig Reeder, M.D. (1)

Results publications

PMID 32499241, PMID 33051668, PMID 22259028, PMID 23393050, PMID 24474568, PMID 25605368, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28771889, PMID 29292843, PMID 29363235, PMID 29475723, PMID 29572391, PMID 30301414, PMID 30562587, PMID 31388792, PMID 33236943, PMID 33492438, PMID 33602316, PMID 34230007, PMID 40292284, PMID 41779512, PMID 42438166, PMID 42827632

NIH funding

P30CA015704 (3), U01CA097452 (2), 2019 (1), P01CA018029 (1), P01CA044991 (1), P01CA078902 (1), P30CA012197 (1), P30CA016058 (1), P30CA016672 (1), P30CA021765 (1), P30CA036727 (1), P50CA136411 (1), U01CA062461 (1), U01CA121947 (1), U01CA132194 (1)